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In Brief
This paper by Husebye and colleagues
directly links heterozygous mutations in
the autoimmune regulator (AIRE) gene to
organ-specific autoimmunity, including
APS-1. The authors show that these
mutations cluster within the first PHD
domain of AIRE and exert a dominant-
negative effect on wild-type AIRE in vitro.
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The autoimmune regulator (AIRE) gene is crucial
for establishing central immunological tolerance
and preventing autoimmunity. Mutations in AIRE
cause a rare autosomal-recessive disease, auto-
immune polyendocrine syndrome type 1 (APS-1),
distinguished by multi-organ autoimmunity. We
have identified multiple cases and families with
mono-allelic mutations in the first plant homeo-
domain (PHD1) zinc finger of AIRE that followed
dominant inheritance, typically characterized by
later onset, milder phenotypes, and reduced
penetrance compared to classical APS-1. These
missense PHD1 mutations suppressed gene
expression driven by wild-type AIRE in a domi-
nant-negative manner, unlike CARD or truncated
AIRE mutants that lacked such dominant capacity.
Exome array analysis revealed that the PHD1
dominant mutants were found with relatively high
frequency (>0.0008) in mixed populations. Our re-
sults provide insight into the molecular action of
AIRE and demonstrate that disease-causing muta-
tions in the AIRE locus are more common than
previously appreciated and cause more variable
autoimmune phenotypes.INTRODUCTIONThe autoimmune regulator (AIRE) is a key player in shaping cen-
tral immunological tolerance to self. AIRE is mainly expressed in
medullary thymic epithelial cells (mTECs), but it is also expressed
to some extent in rare hematopoietic populations of lymph nodes
(Gardner et al., 2008). In mTECs, AIRE induces the expression of
thousands of tissue-restricted proteins, which are presented on
major histocompatibility complex class I (MHC-I) and MHC-II
molecules to developing T cells percolating through the thymic
medulla. This ‘‘projection of self’’ by mTECs is essential for the
elimination of auto-reactive T cells, either via clonal deletion (Ta-
niguchi and Anderson, 2011) or via their conversion into Foxp3+
regulatory T cells (Cowan et al., 2013); a critical step for the
induction of functional immunological tolerance to self and pre-
vention of autoimmunity (Taniguchi and Anderson, 2011).
In humans, mutations in AIRE cause autoimmune polyendo-
crine syndrome type 1 (APS-1), also called autoimmune polyen-
docrinopathy-candidiasis-ectodermal dystrophy (APECED), a
rare autosomal-recessive disease characterized by autoimmune
attack against peripheral (mainly endocrine) tissues, as well as
by generation of various autoantibodies, including interferon-
specific autoantibodies (Meager et al., 2006). The majority of
APS-1 patients develop at least two (diagnostic dyad) of the
three main components, including adrenocortical insufficiency,
hypoparathyroidism, and chronic mucocutaneous candidiasis
(Ahonen et al., 1990; Husebye and Anderson, 2010). In addition,
premature ovarian insufficiency, pernicious anemia, vitiligo,Immunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc. 1185
Figure 1. APS-1 Family with Dominant
Inheritance
(A) Pedigree showing the North-African/Norwegian
family with the dominantly inherited p.C311Y
mutation. The lower panel shows the heterozy-
gous mutation in exon 8 revealed by Sanger
sequencing.
(B) Transcriptional regulation by WT AIRE and the
different mutations. The AIRE-regulated gene
keratin 14 (KRT14) was tested together with the
AIRE-independent gene cyclin H (CCNH) and
normalized against the endogenous control beta2-
microglobulin (B2M). Cells were transfected with
various amounts of WT AIRE andmutants, alone or
in combinations. The results are shown as fold
difference (FD) compared to cells transfected only
with WT AIRE (dotted line); error bars represent
SEM of three independent experiments. *p < 0.05,
**p < 0.0001.
See also Figures S1 and S2 and Tables S1 and S4.alopecia, enamel hypoplasia, and keratitis are common compo-
nents. The disease typically manifests in childhood, but milder
forms with late onset are seen, which are not always initially
recognized as APS-1.
About 100 APS-1-causing mutations have been found
throughout AIRE (http://www.hgmd.cf.ac.uk; Ferguson et al.,
2008). All are assumed to be inherited in an autosomal-recessive
manner, except for onemutation in the SAND domain, p.G228W,
which follows a dominant inheritance pattern (Cetani et al.,
2001). Because AIRE is known to operate as a homo-oligomer
(Kumar et al., 2001; Pitka¨nen et al., 2000), it is rather surprising
that only one mono-allelic mutation in the AIRE locus has been
linked to APS-1 and/or other forms of organ-specific autoim-
mune disorders so far.
Based on analysis of human patients followed by biochemical
and population analyses, we report a group of novel mono-allelic
AIRE mutations. These mutations clustered within the first plant
homeodomain (PHD1) zinc finger domain and were associated
with organ-specific autoimmune diseases of varying penetrance
and severity, which often did not match the diagnostic criteria1186 Immunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc.for APS-1. Furthermore, we delineated
the molecular mode of action by which
these unique mutations interfered with
the function of wild-type (WT) AIRE pro-
tein. Our results provide insight into the
molecular action of the AIRE protein and
indicate that disease-causing mutations
in theAIRE locus aremuchmore common
than previously thought and can cause
more variable autoimmune phenotypes.
RESULTS
Novel p.C311Y AIRE Mutant Exerts
a Dominant-Negative Effect
This study was initiated by the discovery
of a heterozygous c.932G>A (p.C311Y)
mutation in AIRE in a North-African pa-
tient (I:2; Figure 1A, Tables 1 and S1) diag-nosed with adult-onset of chronic mucocutaneous candidiasis,
adrenal insufficiency, enamel dysplasia, pernicious anemia,
partial diabetes insipidus, and interferon omega autoantibodies
(Figure 1A). Importantly, no other mutations or copy-number
variations were detected. The patient’s family history revealed
a daughter (II:1, with partner 1) who had hypoparathyroidism,
enamel dysplasia, primary ovarian insufficiency, autoimmune
gastritis, pernicious anemia, and the same mono-allelic
p.C311Y alteration indicating dominant inheritance. With his
second partner (I:3), the patient had four children, three of
whom carried the mono-allelic p.C311Y alteration and devel-
oped various forms of autoimmunity. One daughter (II:2) had
alopecia areata and nail dystrophy on one of ten finger nails,
another daughter (II:4) had hypoparathyroidism and primary
ovarian insufficiency, and a son (II:3) was diagnosedwith autoan-
tibodies against tyrosine hydroxylase (often associated with
APS-1) (Hedstrand et al., 2000) but no other autoimmune mani-
festations (Figure 1A, Tables 1 and S1). To exclude autosomal-
recessive inheritance at the AIRE locus, we performed microsat-
ellite markers analysis, which confirmed that the affected
children indeed inherited different maternal AIRE alleles (Figures
1A and S1).
We next analyzed whether p.C311Y could repress the tran-
scription-transactivation potential of WT AIRE in a dominant-
negative manner. To this end we utilized the human thymic
epithelial 4D6 cell line, which was transfected with either WT-
AIRE and/or mutated AIRE expression vectors. Alterations in
the CARD domain (p.L28P) and the major Finnish mutation
(p.R257*) were used as recessive controls, and p.G228W was
used as a dominant-negative control. We then measured the
mRNA expression of a panel of AIRE-dependent (KRT14,
S100A8, and IGFL1) and -independent (CCNH and PRMT3)
genes (Giraud et al., 2012). As expected, WT AIRE induced
strong expression of all analyzed AIRE-dependent genes,
whereas p.C311Y, p.G228W, p.L28P, and the deleterious major
Finnish mutation p.R257* did not (Figures 1B and S2). No differ-
ences among the WT AIRE or AIREmutants were seen for AIRE-
independent genes (Figures 1B and S2). Strikingly, when 4D6
cells were co-transfected with different ratios of WT AIRE and
the above mutants, p.C311Y completely abolished the ability
of WT AIRE to induce expression of AIRE-dependent genes (Fig-
ures 1B and S2), as did the previously reported SAND domain
mutant p.G228W (dominant-negative control) (Su et al., 2008).
Conversely, neither p.R257* nor the p.L28P CARD mutation
showed this inhibiting effect (recessive controls). Taken
together, these data validate that the p.C311Y mutant exerted
a dominant-negative effect on WT AIRE function, both in vitro
and in human patients.
Identification of Dominant-Negative Variants of AIRE
Because the phenotype in family A segregated with a heterozy-
gousmutation in AIREwith an inhibitory effect on transcription of
AIRE-dependent genes, we asked whether there might be more
dominant AIREmutations. To test this hypothesis, we generated
a panel of expression vectors with reported disease-causing
mutations including several located in the PHD1, CARD, and
SAND domains (Figure 2A). First we tested the dominant-
negative effect of AIRE mutants in co-transfection experiments
with WT AIRE in 4D6 cells. Similarly to the p.C311Y alteration,
virtually all missense alterations in the PHD1 finger, including
p.E298K, p.V301M, p.C302Y, p.R303P, p.G305S, p.D312N,
and p.P326L, revealed a dominant-negative effect on AIRE-
dependent genes (Figures 2B and S3, Table S2). Interestingly,
the dominant-negative effect of p.V301M varied with the
downstream gene tested (Figures 2B and S3), which was sur-
prising but reproducible in several independent experiments. In
contrast, most of AIRE’s CARDmutants, as well as the truncated
PHD1 mutant p.C311*, revealed a clear recessive pattern, and
the common p.C322del13, p.R328Q, and p.C446G displayed
only a partial dominant effect (Figures 2B and S3, Table S2).
Conversely, p.R471C (PHD2 domain) had no effect on AIRE-
dependent gene transcription (Figures 2B and S3, Table S2).
As expected, AIRE-independent transcriptional activity was not
affected in any of these analyses (Figures 2B and S3). For un-
known reasons, WT and mutated AIRE induced higher levels of
expression of the AIRE-dependent genes than WT alone for
some of the mutants, in particular p.R257* (Figures 1B and 2B).
This series of experiments demonstrated that the heterozy-
gous mutations in AIRE could be segregated into three groupsaccording to their potential to impact on the transcription-
transactivation potential of WT AIRE in (1) dominant-negative,
(2) recessive, and (3) partial dominant-negative manners. More-
over, our data revealed that most of the mutations operating in a
dominant-negative manner were clustered within the PHD1
finger, while most recessive mutations were clustered within
the CARD domain.
Dominant-Negative Mutants Physically Co-localize with
WT AIRE
To better understand the unique properties of the dominant mu-
tants, we next analyzed their nuclear localization patterns. 4D6
cells were co-transfected with red fluorescent protein (RFP)-
tagged WT AIRE plasmids together with expression vectors
encoding individual AIRE mutants tagged with enhanced green
fluorescent protein (EGFP). Importantly, all dominant mutants,
including the PHD1 missense mutations, localized in nuclear
speckles typical for WT AIRE and co-localized with WT AIRE
protein (yellow overlay) (Figures 3A and S4, Table S3). In
contrast, recessive CARD mutants (p.L28P, p.LL28_29PP;
p.Y90C; p.L97P), which are thought to disrupt AIRE homo-oligo-
merization (Kumar et al., 2001; Pitka¨nen et al., 2001), failed to
provide the same speckled pattern and instead stained diffusely
throughout the nucleus when transfected alone. In co-trans-
fections, however, all CARD mutants partly co-localized with
WT AIRE, indicating that when co-expressed, some functional
oligomers are able to form.
Virtually all analyzed PHD1 mutants demonstrated a domi-
nant-negative effect, so we sought to gain more insights about
the impact of these mutants on molecular structure of this
domain. Specifically, in silico analysis predicted that the
p.C311 residue is crucial for chelating Zn2+ and thereby is critical
for correct folding of the PHD1 finger. Indeed, a substitution of
the cysteine with tyrosine predicts disruption of PHD1 folding
(Figure 3B; Chakravarty et al., 2009). Additional structural ana-
lyses revealed that many of the reported missense mutations
changed amino acids that were conserved among different spe-
cies (Figures 3B and S5; Bjo¨rses et al., 2000; Org et al., 2008;
Spiliotopoulos et al., 2012) and could similarly affect the Zn2+-
binding or folding of the domain.
Taken together, these data suggested that most of the PHD1
mutants could, unlike their CARD mutant counterparts, physi-
cally associate with WT AIRE in nuclear speckles and form a
homo-oligomer, which was however not functional due to
dysfunctional PHD1 fingers.
Proof of Concept: Additional PHD1 Dominant-Negative
AIRE Mutations Segregate with Organ-Specific
Autoimmunity
Our in vitro analyses predicted that in addition to the p.C311Y
alteration, more dominant mutations were clustered within the
PHD1 finger and might therefore similarly cause organ-specific
autoimmunity in human patients. To validate this hypothesis,
we performed a thorough analysis of the patient cohorts avail-
able to us. First, we reinvestigated a previously described
case, in which p.C311Y had been reported as a compound het-
erozygous mutation with p.R257* in two Finnish siblings with
childhood-onset of APS-1 (Table 1 [family B, II:3 and II:4], Fig-
ure 4A, and Table S1; Bjo¨rses et al., 2000). Re-sequencingImmunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc. 1187
Table 1. Families with Heterozygous Mutations in AIRE, Their Manifestations, and Autoantibodies
Familya Patient YoB Alteration Manifestationsb Organ-Specific Autoantibodiesc Cytokine Autoantibodiesd
HLA Class II Genotypes
Stratified to AI Riske
A I:2 1951 p.C311Y;WT CMC*, AI*, PA, PDI, EH SCC IFN-u, IFN-a2 neutral
II:1 1971 p.C311Y;WT HP*, PA, EH, POI NALP-5 IFN-u, IFN-a2 protective
II:2 1988 p.C311Y;WT AA, nail dystrophy – IFN-u, IFN-a2 neutral
II:3 1990 p.C311Y;WT – TH – protective
II:4 1995 p.C311Y;WT HP*, POI NALP-5 IFN-u, IFN-a2 neutral
II:5 1998 WT;WT – – – protective
B I:2 1928 p.C311Y;WT PA, blind, T2D 21-OH, NALP-5, AADC, IF – neutral
II:1 1959 p.R257*;WT L, oral cancer – – protective
II:3 1961 p.C311Y;p.R257* CMC*, AI*, POI, A 21-OH, SCC, 17-0H, AADC, TH IFN-u, IFN-a2, IL-17F, IL-22 protective
II:4 1965 p.C311Y;p.R257* HP*, CMC*, AI*, POI, A 21-OH, SCC, 17-OH, TPH-1, NALP-5 IFN-u, IFN-a2, IL-17F, IL-22 protective
III:1 1984 p.C311Y;WT PA, V GPCA, IF – neutral
C I:2 1955 p.V301M;WT AI*, AT, POI 21-OH, AADCf IL-17F very high
II:1 1977 WT;WT – NA NA NA
II:2 1980 p.V301M;WT – – IL-17F neutral
D – 2010 p.C302Y;WT HP* 21-OH, NALP-5 IFN-u NA
E – 2001 p.C302Y;WT HP* NALP-5 IFN-u NA
F I:1 1935 p.P326L;WT – – – neutral
I:2 1943 p.P326L;WT – – – neutral
I:3 1943 WT;WT – – – intermediate
I:4 1944 p.P326L;WT low B12 GPCA – high
II:1 1967 p.P326L;WT – – – intermediate
II:3 1972 p.P326L;WT AI*, PA, V, hypothyroidism 21-OH – high
II:4 1974 p.P326L;WT – TPH-1 – high
II:5 1984 WT;WT – GAD, TPH-1 – intermediate
III:1 1992 p.P326L;WT V GPCA – intermediate
III:2 2005 p.P326L;WT V NA NA intermediate
G I:1 – NA PA NA NA NA
I:2 – NA no autoimmunity NA NA NA
II:1 1934 NA no autoimmunity NA NA NA
II:2 – NA PA, hypothyroidism,
cirrhosis
NA NA NA
II:3 – NA PA NA NA NA
III:1 1959 WT;WT no autoimmunity NA NA NA
III:2 p.G305S;WT PA IF NA
III:3 1972 p.G305S;WT no autoimmunity NA NA NA
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.AIRE in this family confirmed the earlier report but also revealed
that one of the affected siblings’ son (III:1) had inherited p.C311Y
but not p.R257*. He manifested with vitiligo and severe
pernicious anemia due to autoimmune gastritis at young age.
Moreover, the maternal grandmother (I:2), also a heterozygous
p.C311Y carrier, was diagnosed with pernicious anemia and
several autoantibodies characteristic of APS-1 (Table 1, Fig-
ure 4A, and Table S1). In contrast, the third daughter (II:1), a
heterozygous carrier of p.R257*, was without detectable
autoantibodies.
Next, we reinvestigated a woman with APS-2 characterized
by adrenal insufficiency, autoimmune thyroid disease, primary
ovarian insufficiency, and autoantibodies characteristic of
APS-I with a mono-allelic c.901G>A (p.V301M) mutation (Ta-
ble 1 [family C], Figure 4A, and Table S1; So¨derbergh et al.,
2000). Her daughter (also with a p.V301M alteration) had auto-
antibodies against IL-17F, which are often found in APS-1
patients. However, she did not present with any additional
autoimmune manifestations at age 30 years. Finally, additional
screening of a large cohort of 85 Russian APS-1 patients and
some of their family members identified a young girl with a
mono-allelic p.C302Y mutation, who developed hypoparathy-
roidism and autoantibodies against interferon omega, NALP-5,
and 21-hydroxylase (Tables 1 [subject D] and S1). Like
p.C311Y, p.C302Y revealed dominant-negative effects on
AIRE-mediated transcription (Figures 2B and S3 and Table
S2). A very similar case with a de novo mono-allelic p.C302Y
alteration was reported by us earlier (Tables 1 [subject E] and
S1; Oftedal et al., 2008).
In summary, our data illustrated that individuals with bi-allelic
disease-causing AIRE mutations developed classic early-onset
APS-1 phenotypes, whereas those carrying one of three different
mono-allelic mutations in the PHD1 finger (p.C311Y, p.V301M,
and p.C302Y) segregated with clear but varying autoimmune
phenotypes, ranging from late-onset classical APS-1 (e.g., I:3,
Figure 1A) to APS-2 (Table 1, Figure 4B, and Table S1) and iso-
lated organ-specific autoimmunity (e.g., vitiligo, PA, and APS-
1-specific autoantibodies).
Increased Frequency of Dominant PHD1 Mutations in
Various Forms of Organ-Specific Autoimmunity
The above findings raised the question whether dominant PHD1
mutations could generally cause organ-specific autoimmunity.
To answer this question, we sequenced the full exon 8 (encoding
the PHD1 finger) in several autoimmune patients and controls
available from our national registry. We first analyzed the pres-
ence of PHD1 mutants in familial cases characterized by the
presence of adrenal insufficiency, autoimmune thyroid disease,
and/or type 1 diabetes (i.e., APS-2 and/or APS-3). Indeed,
among 41 such families, we identified one family with three
family members bearing a mono-allelic c.977C>T (p.P326L)
mutation (Table 1 [family F], Figure 4A, and Table S1). The
mother (II:3) was diagnosed with autoimmune thyroid disease,
adrenal insufficiency, pernicious anemia, and vitiligo. Both of
her children acquired vitiligo at 10 (III:1) and 7 (III:2) years of
age, respectively.
Furthermore, because pernicious anemia, vitamin B12 defi-
ciency, and/or vitiligo seemed to be often associated with het-
erozygous PHD1 mutations in previous cases (Figure 4B), weImmunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc. 1189
Figure 2. Heterozygous Mutations in AIRE
and the Effect on Gene Regulation
(A) Model of the AIRE protein with domains and
common mutations classified as recessive (black)
and dominant (red).
(B) The AIRE-regulated gene KRT14 (red bars) and
CCNH not regulated by AIRE (blue bars). Tran-
scriptional regulation by WT AIRE and mutants
was performed as described in Figure 1B. The
results are shown as fold difference (FD)
compared to cells transfected only with WT AIRE
(dotted line), error bars representing SEM, of two
independent experiments. *p < 0.05, **p < 0.0001.
See Figure S3 and Table S2.next screened large cohorts of patients with these conditions.
Among 177 probands and 26 affected relatives with pernicious
anemia, we identified several dominant-negative PHD1mutants.
First, we identified a patient with a heterozygous c.913G>A
(p.G305S) mutation who was intrinsic factor (IF) antibody posi-
tive and developed severe anemia and neuropathy at age 43
(Table 1 [family G], Figure 4A, and Table S1). Her mother (II:2)
and maternal grandfather (I:1) were reported to have pernicious
anemia, and the mother also suffered from hypothyroidism and
cirrhosis. Her sister (III:3) with p.G305S reported no autoimmu-
nity. p.G305S is close to the zinc binding site and predictably
disrupts the zinc finger structure. Not surprisingly, the domi-
nant-negative effect on gene transcription was evident (Fig-
ures 2B and S3 and Table S2). Another patient in this cohort
developed intrinsic factor antibody-positive pernicious anemia
at age 81 years and was heterozygous for both c.946C>T
(p.R316W) and the common c.967–979del13bp (p.C322del13)
mutation on the same allele (Tables 1 and S1 [subject H]). Both1190 Immunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc.p.R316W and p.C322del13 were pre-
dicted to have a partial dominant-nega-
tive effect.
Similarly, among 170 patients with iso-
lated and familial (n = 64) vitiligo, a female
who developed acrofacial vitiligo at age
21 years had gastric parietal cell autoanti-
bodies, low normal serum vitamin B12
level, and a heterozygous mutation in
c.983G>A (p.R328Q) (Tables 1 [subject I]
and S1). Like p.P326L, a mutation in this
C-terminal part of PHD1 does not disrupt
the histone binding site but still displays
an incomplete inhibition of AIRE-depen-
dent gene transcription (Figures 2B and
S3, Table S2). AIRE sequencing revealed
that the patient also had p.V484A, a
sequence variant that hasbeendescribed
in a patient with alopecia and nail
dystrophy (Buzi et al., 2003). We were
unfortunately unable to perform an allele
discrimination assay in this patient.
Importantly, sequencing of 450 control
blood donors did not reveal the presence
of any of the dominant-negative PHD1
mutations and demonstrated that domi-nant PHD1 mutations were clearly over-represented among
patients suffering from various forms of organ-specific autoim-
munity. Based on the above data, we propose that heterozygous
mutations in the PHD1 domain of AIRE exert a dominant-nega-
tive effect onWT AIRE (Figure 5A) and that APS-1 can be divided
into classical (recessive) and non-classical (dominant) forms
(Figure 5B).
The Frequency of Dominant-Negative PHD1 AIRE
Mutations in Populations
To better estimate the frequency of some of the dominant-
negative PHD1 AIRE mutations, we analyzed multiple exome
chip datasets that were available, containing some of the
PHD1 AIRE sequence variations. Specifically, sequence anal-
ysis from existing exome chip datasets from a total of 1,670
Scandinavian individuals (healthy controls [n = 637] and pa-
tients with attention deficit [n = 589] or movement disorders
[n = 444]) revealed the minor allele frequency of p.V301M to
Figure 3. Subcellular Co-localization of the Mono-allelic Variants
(A) Confocal fluorescence images displaying the subcellular localization of
WT-RFP-AIRE (red) and mutant-EGFP-AIRE (green) proteins. Overlay images
shows the degree of co-localization (yellow). Nuclei were visualized with DAPI
counterstain (blue).
(B) The solution structure of the PHD1 domain of AIRE, showing the Zn2+-
ligating residues. Zn2+ shown as sphere and cysteines as sticks. The C311
mutation hotspot is shown in cyan (right). Modeling shows that the p.C311Y
alteration would disrupt Zn2+ ligation.
See also Figures S4 and S5 and Tables S2 and S3.be 0.00089 (i.e., 3 out of 1,667 persons), whereas other
covered alterations (p.G303S, p.R303Q, and p.R257*) were
not found. The relatively high frequency of the p.V301M
dominant mutant was further validated by additional datasets
obtained from mixed populations in public databases, including
the recently published data from The Broad Institute (covering
more than 60,000 individuals; Exome Aggregation Consortium
[ExAC], http://exac.broadinstitute.org), 1000 Genomes data-
base (http://www.1000genomes.org), and the Washington
Database (6,000 individuals; Exome Variant Server, NHLBI
GO Exome Sequencing Project [ESP], http://evs.gs.
washington.edu/EVS/). All of the above databases confirmed
and broadened these findings and demonstrated that domi-
nant-negative PHD1 mutations were present with minor allele
frequency reaching 0.0009 (mainly p.V301M and p.R303Q) in
the general population (Table 2). It should be stressed, how-
ever, that most of the dominant-negative PHD1 variants were
not covered on these exome chips, suggesting that the actual
frequency might be even higher.DISCUSSION
Many proteins are active only in the form of a multimeric com-
plex, composed of two or more copies of the same protein. It
is well established that in many of these cases, mono-allelic
mutations can completely or partially disrupt the structure and
thereby the activity of the entire multimeric complex in a domi-
nant-negative manner. Because AIRE is shown to form a
homo-tetramer in vivo (Kumar et al., 2001), it is rather surprising
that only one mono-allelic mutation in the AIRE locus has been
linked to APS-1 and/or other forms of organ-specific autoim-
mune disorders so far. We identified several novel heterozygous
missense mutations in AIRE, primarily clustered within its PHD1
zinc finger, that were characterized by dominant inheritance,
later debut, milder phenotypes, and reduced penetrance. Inter-
estingly, most autosomal-recessivemissensemutations causing
APS-1 are predominantly found within the CARD domain
(Bjo¨rses et al., 2000), which suggested that the recessive or
dominant character of a given mutation is, to a large extent,
determined by its position within the AIRE protein. This probably
reflects the different and unique roles of the individual domains of
the AIRE protein. Specifically, whereas the CARD domain is
shown to be critical for AIRE homo-oligomerization and speckled
nuclear localization (Bjo¨rses et al., 1999; Kumar et al., 2001),
the PHD domain of AIRE functions as an epigenetic reader,
specifically recognizing unmethylated lysine 4 on histone 3
(H3K4me0) (Org et al., 2008). The PHD1 domain is shown to be
absolutely critical for AIRE’s transcription-transactivation activ-
ity, as well as for its capacity to prevent multiorgan autoimmunity
in transgenic mouse models (Bjo¨rses et al., 2000; Koh et al.,
2008, 2010). In silico simulations revealed that the PHD1 resi-
dues N295-C310 were important in the intermolecular interac-
tions with histone H3 residues. PHD1 is unable to interact with
H3K4me0 if the zinc chelating cysteines are mutated, as is the
case for C311Y (Bottomley et al., 2005). The formation of salt
bridges between the side chains of H3 residue R2 and D312 is
shown to be crucial for binding specificity (Koh et al., 2008), ex-
plaining why the structure is highly conserved in AIRE among
different species and also in PHD-zinc finger domain-containing
proteins.
Unlike the PHD1 mutants, mutations clustered within the
CARD domain of AIRE did not exert any dominant-negative ef-
fect. In homozygotes, these mutations impact AIRE oligomeriza-
tion and correct nuclear localization (Bjo¨rses et al., 1999; Kumar
et al., 2001; Pitka¨nen et al., 2001), yet they might be able to form
oligomers when expressed along with WT AIRE. Interestingly,
truncating AIRE mutations such as p.R257* and p.C311* also
behaved in a recessive manner, in spite of their ability to co-
localize and interact with WT AIRE. This suggested that the
above truncations do not disrupt the core structure of the AIRE
complex, necessary for its biological activity. Such core struc-
ture probably involves formation of functional dimers within the
truncated tetramer.
It is therefore not entirely surprising that mono-allelic and
dominant-negative mutations in this domain impacted the
structure and thus the activity of the entire AIRE tetramer.
However, such dominant effects seemed to follow incomplete
inheritance, because most of the patients developed milder
phenotypes with later onset compared to patients withImmunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc. 1191
Figure 4. The AIRE PHD1 Domain
(A) Pedigrees of families with p.C311Y (family B), p.V301M (family C), p.P326L
(family F), and p.G305S (family G) AIRE alterations.
(B) The AIRE protein with its different domains. The mutations investigated in
this study are shown, color-coded for dominant (red) and recessive (black).
The AIRE PHD1 is shown, together with cake diagrams, each representing one
patient depicting clinical manifestations and autoantibodies.
See also Table S1.classical, autosomal-recessive APS1. This could be because
the AIRE tetramers still have some residual activity, and/or
that some pure WT AIRE tetramers were still formed and
were sufficient to induce some level of self-tolerance. More-
over, the extent of the dominant effect seemed to depend
on which residue is mutated. Our results suggested that muta-
tions in residues 302 and 311 resembled more classical APS-1
than other mutations, although we observed large diversity
within the two families with p.C311Y studied here.
The genetic contribution of AIRE to autoimmune diseases
other than APS-1 has been studied by us and others, but in
most cases only SNPs or a few common mutations are
analyzed, thereby overlooking rare mutations or large deletions
(Jin et al., 2007; Pforr et al., 2006; Thomson et al., 2007; To¨ro¨k
et al., 2004; Turunen et al., 2006; Vaidya et al., 2000). Although
some heterozygous mutations in AIRE are associated with
autoimmunity in single patients, a dominant-negative effect
on AIRE function was not considered in these cases. Here,1192 Immunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc.we demonstrated that the heterozygous variants observed in
the families as well as other mutations analyzed within AIRE
exon 8 had an inhibitory effect on AIRE-mediated transcription.
This contrasts to classical APS-1 with recessive inheritance
and early presentation (mean age 9.1 years, 90% develop all
three components by age 20 years) (Wolff et al., 2007). Organ-
specific autoimmunity in the heterozygous cases presented
later (mean age 24.4 years, n = 12) and progressed more
slowly, fewer patients developed the diagnostic dyad, and
the penetrance was incomplete. This is reminiscent of auto-
immune lymphoproliferative syndrome, which shows 60%
penetrance among family members harboring the same hetero-
zygous gene mutation (Price et al., 2014), or to the incomplete
penetrance seen in families carrying heterozygous CTLA4
mutations (Kuehn et al., 2014). More importantly, the unusual
heterozygous cases might not even be recognized as APS-1
because many patients masqueraded as common types of or-
gan-specific autoimmunity in one or several organs. Thus, the
original classification of APS-1 as a strictly autosomal-reces-
sive disease (with one exception [Cetani et al., 2001]) is obso-
lete. Instead, we propose that APS-1 exists in two forms: (1)
‘‘classical,’’ characterized by recessive inheritance, presence
of at least two of three main components, and interferon anti-
bodies; and (2) ‘‘non-classical,’’ characterized by dominant het-
erozygous mutations mainly in AIRE’s PHD1 zinc finger and a
milder, less penetrant autoimmune phenotype. Families with
dominant clustering of organ-specific autoimmunity, especially
when pernicious anemia and/or vitiligo manifests at early age,
might have such mutations, although the clinical phenotype
might be expanded when larger materials are investigated.
Furthermore, it is reasonable to assume that mutation carriers
have a significant risk for polyendocrinopathy, which should
be reflected in their follow-up programs. Moreover, autoanti-
bodies against interferons, hallmarks of classical APS-1, were
much less prevalent in the non-classical form, probably reflect-
ing some residual AIRE function at least for some of the PHD1
mutations.
Because deep DNA sequencing of thousands of different pa-
tients was beyond the scope of the current study, we cannot
provide accurate estimates of the prevalence of non-classical
APS-1 because a population cohort with autoimmune pheno-
types was not available. Based on our own data and publicly
available databases representing healthy individuals and pa-
tients with various non-autoimmune conditions in different
ethnic groups, a conservative estimate puts dominant AIRE
mutations at a genotype frequency of one to two persons per
thousand in the general population, not restricted to Scandina-
via as indicated in literature reports (Cervato et al., 2010;
Ferrera et al., 2007; Stolarski et al., 2006; Vogel et al., 2001).
However, further studies are needed to establish the preva-
lence and risk associated with mutations in the PHD1 domain
in larger populations.
In conclusion, this study demonstrates that AIRE mutations
associate with common organ-specific autoimmunity with a var-
iable phenotype ranging from classical APS-1 to a non-classical
form that mimics common organ-specific autoimmunity. Finally,
our study provides important insights into the molecular mode of
action of the AIRE protein and highlights unique structural prop-
erties that are required for AIRE’s biological activity.
Figure 5. Dominant Mutations in AIRE and Organ-Specific
Autoimmunity
(A) Schematic illustration of recessive and dominant AIRE mutations. The
homozygous p.R257* truncated protein can form oligomers, but they lack
critical domains. In the heterozygous state, p.R257* does not interfere with
WT AIRE. PHD1 mutants can form oligomers but AIRE lacks transcriptional
activity because of its putative interaction with WT AIRE. Formation of a small
fraction of WT:WT oligomers might account for some induction of tolerance
and a milder autoimmune phenotype.
(B) Manifestations and autoantibodies in patients with recessive (from Meager
et al., 2006; Perheentupa, 2006; Wolff et al., 2007) and dominant (this study)
mutations. Abbreviations are as follows: AI, adrenocortical insufficiency; CMC,
chronic mucocutaneous candidiasis; HP, hypoparathyroidism; PA, pernicious
anemia; V, vitiligo.EXPERIMENTAL PROCEDURES
Patients and Healthy Subjects
A detailed description of patient and control cohorts is given in the Supple-
mental Data. Use of human material was approved by local ethics committees
and all individuals included signed informed consent.
AIRE Sequencing, Copy-Number Analysis, andMicrosatellite Typing
DNA was extracted from patient or control EDTA blood samples according to
standard protocols. All patients and controls were analyzed for nucleotide
changes in AIRE (GenBank: AJ009610) exon 8, which contains the PHD1
domain. The 14 exons in AIRE were sequenced in the patients with nucleotide
changes in exon 8 by PCR and sequencing as previously described (Wolff
et al., 2007). Copy-number analysis was performed by duplex TaqMan real-
time PCR assay as described previously (BøeWolff et al., 2008), using primers
and probes for AIRE exon 1 and 9. In brief, a duplex TaqMan real-time PCR
assaymeasured the fluorescent signal from the target (AIRE) and the reference
gene (RNaseP [Ribonuclease P]) (Applied Biosystems), detected using
different probes. RNasP is known to present in two copies in the genome,
and using a standard curve for each gene the number of AIRE copies wascalculated as the relative relationship between the signals from AIRE and
RNaseP. Microsatellite typing of the AIRE region was performed according
to Myhre et al. (2004). The samples used to estimate population frequencies
for AIRE mutations were genotyped on HumanExome 12v1_B (ADHD study)
and HumanCoreExome 12v1-1 (movement disorders study) Bead chips,
respectively (Illumina).
Assay of Autoantibodies
Autoantibodies against interferon (IFN)-u, IFN-a2, interleukin (IL)-17F, IL-22,
and organ-specific enzymes typical of APS-1 were assayed by radioligand
binding assays based on in vitro transcribed and translated proteins, as previ-
ously described (Husebye et al., 1997; Oftedal et al., 2008).
Plasmid Construction
The plasmids svPoly and pEGFP-C1 containing human wild-type (WT) AIRE
andAIRE-C311Y, respectively, were kind gifts fromDr. IsmoUlmanen (Depart-
ment of Molecular Medicine, National Public Health Institute). HumanWT AIRE
was also contained in pTagRFP-C vector (Evrogen) by subcloning. The
different mutations in AIRE were introduced by site-directed mutagenesis
(QuikChange II Site-Directed Mutagenesis Kits [Agilent Technologies]) using
primers designed by the web-based program PrimerX (http://www.
bioinformatics.org/primerx/) (see Supplemental Experimental Procedures for
primers). All plasmids were verified by sequencing.
Transfection and RNA Extraction
4D6 cells, a kind gift from Professor Christophe Benoist (Harvard Medical
School), were grown in RPMI 1640 (Sigma-Aldrich) supplemented with 10%
(v/v) fetal bovine serum, 10 mM HEPES buffer, 1% (v/v) non-essential amino
acids (Lonza), 2 mM L-glutamine (Lonza), 100 U/ml penicillin, and 100 mg/ml
streptomycin (Lonza) at 37Cwith 5%CO2 in a humidified incubator. For trans-
fection, cells were plated at a density of 53 105 cells per well in a 6-well plate
and left overnight. Samples (3.3 mg) of the svPoly plasmids were added to a
total volume of 157 ml supplemented RPMI 1640 (without penicillin or strepto-
mycin), mixed with 8.3 ml of Fugene HD transfection reagent (Promega Corpo-
ration), and incubated for 5min at room temperature before being added to the
cells. The cells were then incubated for 24 hr before total RNA was extracted
by RNeasy Mini Kit (QIAGEN) according to the manufacturers’ protocol,
including in-column DNase treatment. cDNA was prepared from 1 mg of total
RNA via a High Capacity RNA-to-cDNA Kit (Applied Biosystems).
Assay of AIRE-Regulated Genes
Genes previously shown to be regulated by AIRE (Abramson et al., 2010) were
analyzed by quantitative PCR using the following primers and probes (Applied
Biosystems): S100 calcium binding protein A8 (S100A8) (Hs0037444264_g1),
keratin 14 (KRT14) (Hs00265033-m1), IGF-like family member 1 (IGFL1)
(Hs01651089-g1), and AIRE (Hs01102906-g1 and Hs01102908-g1). Results
were compared to beta2-microglobulin (B2M) (4333766) as endogenous con-
trol, and the AIRE-independent genes cyclin H (CCNH) (Hs00236923_m1) and
protein arginine methyltransferase 3 (PRMT3) (Hs00411605_m1). Datasets of
each primer pair were normalized to B2M. Ct values from cells transfected
with svPoly harboring the different mutations or the empty svPoly plasmid
were then subtracted from the Ct values obtained after transfection with
svPoly harboring WT-AIRE. To mimic a heterozygous state, and evaluate the
effect of gene dosage, WT-AIRE and AIRE mutants (G228W-AIRE, R257*-
AIRE, C311Y-AIRE, and L28P-AIRE) were transfected in ratios of 50% to
75% WT-AIRE. For the rest of the mutants, they were transfected as 100%
mutant or 50%mutant with 50%WT AIRE. The fold difference was calculated
as 2  {Ct((target gene)  Ct(B2M))  (Ct(test sample)  Ct(calibrator sam-
ple))}, with test samples defined as the different mutants of AIRE and calibrator
as WT-AIRE. The results are shown as the mean of minimum two biological
parallels, and a two-tailed t test (GraphPad Prism v.5.02) was used for p
values.
Immunofluorescence
Human 4D6 cells were plated on 18-mm sterile coverslips in 6-well plates at a
density of 53 105 cells per well and allowed to grow overnight. The cells were
then transfected with human EGFP-AIRE and/or RFP-AIRE fusion plasmids
using Fugene HD transfection reagent according to the manufacturers’Immunity 42, 1185–1196, June 16, 2015 ª2015 Elsevier Inc. 1193
Table 2. Minor Allele Frequency of Missense Mutations within AIRE Exon 8
Variant Protein Effect
Norwegian Exome Data ExAC Browser 1000 Genomes Genome Variant Server
Allele Count Allele No. MAF Allele Count Allele No. MAF Allele Count Allele No. MAF Allele Count Allele No. MAF
21:45710990 G / A p.E298K NA NA NA 1 121632 0.000008222 – – NA NA NA NA
21:45710995 T / G p.C299W NA NA NA 1 121584 0.000008225 – – NA NA NA NA
21:45710999 G / A
rs150634562
p.V301M 3 3340 0.00089 111 121496 0.0009136a 2 5006 0.00039 5 13001 0.00038
21:45711005 C / T p.R303W NA NA NA 1 121256 0.000008247 – – ND 2 13002 0.00015
21:45711006 G / A
rs139808903
p.R303Q ND ND ND 22 121228 0.0001815b – – NA NA NA NA
21:45711014 G / A p.G306R NA NA NA 1 121096 0.000008258 – – NA NA NA NA
21:45711025 C / G
rs74162062
p.I309M NA NA NA 14 120718 0.0001160c – – ND NA NA NA
21:45711044 C / T
rs139874934
p.R316W NA NA NA 4 119274 0.00003354 2 8596 0.00023 2 13002 0.00015
21:45711044 C / G
rs139874934
p.R316G NA NA NA 1 119274 0.000008384 – – NA NA NA NA
21:45711045 G / A p.R316Q NA NA NA 4 119214 0.00003355 1 760 0.0013 NA NA NA
21:45711054 A / C p.H319P NA NA NA 3 117232 0.00002559 – – NA NA NA NA
21:45711075 C/A
rs179363885
p.P326Q NA NA NA NA NA NA – – ND NA NA NA
21:45711075 C/T
rs179363888
p.P326L NA NA NA NA NA NA – – ND NA NA NA
21:45711080 C / T
rs74162063
p.R328W ND ND ND 21 116188 0.0001807d – – ND 10 12982 0.00077
21:45711081 G / A p.R328Q NA NA NA 4 116112 0.00003445 – – ND NA NA NA
21:45711092 A / C p.S332R NA NA NA 1 114898 0.000008703 – – NA NA NA NA
This table shows the allele count, allele number, and minor allele frequency (MAF) of AIRE PHD1. Data are obtained from different sources: the Norwegian exome data are from healthy controls and
patients with ADHD and movement disorders, the ExAC Browser includes 60,706 unrelated individuals from various disease-specific and population studies, the Genome Variant Server includes
sequences from 6,503 individuals with heart, lung, and blood disorders, and the 1000 Genomes Project includes 2,577 individuals with a mixed background. Abbreviations are as follows: NA, not
analyzed in this dataset; ND, no frequency determined.
aThe majority mutations are found in European (minus Finnish), followed by Finnish, South Asian, and African populations.
bThe majority mutations are found in European (minus Finnish), followed by Latino populations.
cThe majority mutations are found in European (minus Finnish), followed by South Asian population.
dThe majority mutations are found in European (minus Finnish), followed by Finnish population.
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protocol. In brief, plasmid DNA was mixed with transfection reagent at a ratio
of 1:2.5 in 157 ml Opti-MEM I Reduced Serum Medium (Invitrogen) and incu-
bated for 7 min at room temperature before being added to the cells. After
24 hr, the cells were washed with PBS (Lonza) and fixed in 4% (w/v) parafor-
maldehyde in PBS for 7 min. Finally, the cells were washed thoroughly with
PBS and ultrapure water before being mounted onto SuperFrost microscope
slides (Thermo Fisher Scientific) with ProLong Gold Anti-Fade Reagent with
DAPI (Invitrogen). Slides were examined under a Zeiss LSM 510 META Laser
Scanning confocal microscope equipped with a 633 Plan-Achromat objec-
tive, and images acquired by excitation at 405 nm (DAPI), 488 nm (EGFP),
and 543 nm (RFP). The imaging was performed at the Molecular Imaging Cen-
ter (Fuge, Norwegian Research Council), UiB, Norway.
Protein Analysis
To verify protein expression, single transfection with WT AIRE, C311Y, R257*,
and G228W were followed by cell lysis by Complete Lysis-M (Roche Diagnos-
tics GmbH), SDS-PAGE, and immunoblot. AIRE polyclonal anti-AIRE antibody
(goat) (1:100 dilution) (Abnova) was used as primary antibody (result not
shown).
Structure Modeling
Sequence alignment was made with Clustal Omega Multiple sequence
alignment tool (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=
clustalo). Modeling of PHD1 was performed with PyMOL and the coordinates
of PDB: 1XWH (Bottomley et al., 2005).
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